To include your compound in the COVID-19 Resource Center, submit it here.

Stapling β-catenin

FOG's stapled peptide could be the first β-catenin inhibitor to reach the clinic

Harvard University professor and serial entrepreneur Greg Verdine’s new start-up, FOG Pharmaceuticals Inc., is using his latest version of stapled peptide technology to block the notoriously undruggable protein, β-catenin, in metastatic colorectal cancer (mCRC).

Stapled peptides are cell-permeable peptides containing a chemical bridge (the staple) that stabilizes the core α-helix, enhancing the binding affinity of the helix and preventing proteolytic degradation.

Read the full 603 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers